'"Targeting tau acetylation could be a new therapeutic strategy against human tauopathies, like Alzheimer's disease and FTD," says co-senior author Eric Verdin, MD, a senior investigator at the Gladstone Institutes. "Given that salsalate is a prescription drug with a long-history of a reasonable safety profile, we believe it can have immediate clinical implications."'
http://medicalxpress.com/news/2015-09-dr...sease.html
http://medicalxpress.com/news/2015-09-dr...sease.html